ADA-SCID 患者中 HCT 的存活率：有何新进展？
HCT survival in ADA-SCID: what's the buzz?
机构信息
Baylor College of Medicine, USA.
出版信息
Blood. 2012 Oct 25;120(17):3392-3. doi: 10.1182/blood-2012-07-443960.
PMID:23100302
Abstract
In this issue of Blood, Hassan et al have turned the spotlight on hematopoietic stem cell transplantation (HCT) of adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). They opened up the curtain of beliefs on this therapy that enables facts to be separated from fiction.
摘要
在本期《Blood》中，Hassan 等人将焦点转向了腺苷脱氨酶（ADA）缺陷型严重联合免疫缺陷（SCID）的造血干细胞移植（HCT）。他们揭开了这一疗法的神秘面纱，使事实与虚构得以区分。
Zotero 插件